A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Primary

Inclusion Criteria:

- Relapsed or refractory histologically confirmed Non-Hodgkin's Lymphoma

- Previously treated with at least 1 therapeutic regimen and relapsed or progressed or
failed to achieve a response after the last regimen

- 18 years of age or older

Primary Exclusion Criteria:

- Received a non-FDA approved investigational agent within the last 4 weeks

- Received cancer therapies (chemotherapy, biological therapy [including
hormonotherapy], radiation therapy or immunosuppressants within the last 3 weeks, 8
weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea

- Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous
HSCT within the last 16 weeks

- Prior history of an allogeneic HSCT

- HIV, AIDS-related lymphoma, central nervous system (CNS) lymphoma, Hepatitis-B or
Hepatitis-C

- Infection requiring antibiotics within the last 4 weeks

- Major surgery within the last 4 weeks

- Pregnant or breast-feeding women

- History of other cancers within the past 5 years